120160-29-4 Usage
Description
1-(1-Methyl-1H-indol-4-yl)ethanone, also known as 4-MeO-AMT, is a chemical compound with a molecular formula C11H11NO. It is a derivative of the psychedelic amphetamine alpha-methyltryptamine (AMT) and has a similar structure and pharmacological effects. 4-MeO-AMT is a potent entactogenic and hallucinogenic drug, known for its stimulating and empathogenic properties. It is a serotonergic psychedelic, acting as a releasing agent and reuptake inhibitor of serotonin, dopamine, and norepinephrine.
Uses
1-(1-Methyl-1H-indol-4-yl)ethanone is used as a psychedelic substance for its entactogenic and hallucinogenic effects. However, it is important to note that 1-(1-Methyl-1H-indol-4-yl)ethanone is not approved for medical use and is classified as an illegal drug in many countries due to its potential for abuse and adverse health effects.
Check Digit Verification of cas no
The CAS Registry Mumber 120160-29-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,0,1,6 and 0 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 120160-29:
(8*1)+(7*2)+(6*0)+(5*1)+(4*6)+(3*0)+(2*2)+(1*9)=64
64 % 10 = 4
So 120160-29-4 is a valid CAS Registry Number.
120160-29-4Relevant articles and documents
Palladium-catalyzed acetylation of arenes
Ramgren, Stephen D.,Garg, Neil K.
supporting information, p. 824 - 827 (2014/03/21)
A simple method for the preparation of aryl methyl ketones is reported. The transformation involves the Pd-catalyzed coupling of an acyl anion equivalent, acetyltrimethylsilane, with aryl bromides to afford the corresponding acetylated arenes in synthetically useful yields. The methodology is tolerant of heterocycles and provides a new method for arene functionalization.
CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES
-
Page 103-104, (2008/06/13)
The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
